Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial

Journal of Diabetes and its Complications

Volumn 28, Issue 5, 2014, Pages 742-749

  Rosenstock, Julio ^a   Fonseca, Vivian ^b   Schinzel, Stefan ^c   Dain, Marie Paule ^d   Mullins, Peter ^e   Riddle, Matthew ^f  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Sanofi Deutschland GmbH   (Germany)

^d SANOFI   (France)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Clinical diabetes; Clinical science and care; Glargine; Hypoglycemia; NPH

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT; LONG ACTING INSULIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK; TIME FACTOR;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RISK; RISK REDUCTION BEHAVIOR; TIME FACTORS;

EID: 84906938191     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.04.003     Document Type: Article

References (37)

1. M. Ali, J. White, C.H. Lee, J.L. Palmer, J. Smith-Palmer, and W. Fakhoury et al. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia Journal of Medical Economics 11 2008 651 670
2. M.P. Allicar, F. Megas, S. Houzard, A. Baroux, F. Le Thai, and B. Augendre-Ferrante Frequency and costs of hospital stays for hypoglycemia in France in 1995 Presse Médicale 29 2000 657 661
3. S.A. Amiel, T. Dixon, R. Mann, and K. Jameson Hypoglycaemia in type 2 diabetes Diabetic Medicine 25 2008 245 254
4. L.A. Bazzano, L.J. Lee, L. Shi, K. Reynolds, J.A. Jackson, and V. Fonseca Safety and efficacy of glargine compared with NPH insulin for the treatment of type 2 diabetes: A meta-analysis of randomized controlled trials Diabetic Medicine 25 2008 924 932
5. M.F. Bullano, I.S. Al-Zakwani, M.D. Fisher, L. Menditto, and V.J. Willey Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products Current Medical Research and Opinion 21 2005 291 298
6. M.F. Bullano, M.D. Fisher, W.D. Grochulski, L. Menditto, and V.J. Willey Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products American Journal of Health-System Pharmacy 63 2006 2473 2482
7. R.J. Cook, and D.L. Sackett The number needed to treat: A clinically useful measure of treatment effect BMJ 310 1995 452 454
8. P.E. Cryer Hypoglycemia is the limiting factor in the management of diabetes Diabetes/Metabolism Research and Reviews 15 1999 42 46
9. P.E. Cryer Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes Diabetologia 45 2002 937 948
10. P.E. Cryer Hypoglycemia, functional brain failure, and brain death Journal of Clinical Investigation 117 2007 868 870
11. B.M. Frier How hypoglycaemia can affect the life of a person with diabetes Diabetes/Metabolism Research and Reviews 24 2008 87 92
12. A. Fritsche, M. Schweitzer, and H.-U. Haring Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial Annals of Internal Medicine 138 2003 952 959
13. D.T. Grima, M.F. Thompson, and L. Sauriol Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada PharmacoEconomics 25 2007 253 266
14. A. Heaton, S. Martin, and T. Brelje The economic effect of hypoglycemia in a health plan Managed Care Interface 16 2003 23 27
15. P.D. Home, A. Fritsche, S. Schinzel, and M. Massi-Benedetti Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine Diabetes, Obesity & Metabolism 12 2010 772 779
16. K. Horvath, K. Jeitler, and A. Berghold et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus Cochrane Database of Systematic Reviews 2007 CD005613
17. L. Jonsson, B. Bolinder, and J. Lundkvist Cost of hypoglycemia in patients with type 2 diabetes in Sweden Value in Health 9 2006 193 198
18. M. Korytkowski When oral agents fail: Practical barriers to starting insulin International Journal of Obesity and Related Metabolic Disorders 26 2002 S18 S24
19. W.C. Lee, S. Balu, D. Cobden, A.V. Joshi, and C.L. Pashos Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data Clinical Therapeutics 28 2006 1712 1725 (discussion 1710-1711)
20. G.P. Leese, J. Wang, and J. Broomhall et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use Diabetes Care 26 2003 1176 1180
21. S. Leichter Is the use of insulin analogues cost-effective? Advances in Therapy 25 2008 285 299
22. J. Lundkvist, C. Berne, B. Bolinder, and L. Jonsson The economic and quality of life impact of hypoglycemia The European Journal of Health Economics 6 2005 197 202
23. M. Massi-Benedetti, E. Humburg, A. Dressler, and M. Ziemen A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes Hormone and Metabolic Research 35 2003 189 196
24. P. McEwan, C.D. Poole, T. Tetlow, P. Holmes, and C.J. Currie Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK Current Medical Research and Opinion 23 Suppl 1 2007 21 31
25. M. Monami, N. Marchionni, and E. Mannucci Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis Diabetes Research and Clinical Practice 81 2008 184 189
26. P. Mullins, P. Sharplin, H. Yki-Jarvinen, M.C. Riddle, and H.U. Haring Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus Clinical Therapeutics 29 2007 1607 1619
27. A.J. Palmer, M. Lammert, and K. Hermansen Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark Ugeskrift for Laeger 170 2008 1250 1254
28. J. Reviriego, R. Gomis, J.P. Maranes, W. Ricart, P. Hudson, and J.A. Sacristan Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia International Journal of Clinical Practice 62 2008 1026 1032
29. G.G. Rhoads, L.S. Orsini, W. Crown, S. Wang, D. Getahun, and Q. Zhang Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine 47 2005 447 452
30. M.C. Riddle, J. Rosenstock, and J. Gerich The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 26 2003 3080 3086
31. J. Rosenstock, V. Fonseca, and J.B. McGill et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: A long-term, randomised, open-label study Diabetologia 52 2009 1778 1788
32. J. Rosenstock, V. Fonseca, and J.B. McGill et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study Diabetologia 52 2009 1971 1973
33. J. Rosenstock, S.L. Schwartz, C.M. Clark Jr., G.D. Park, D.W. Donley, and M.B. Edwards Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin Diabetes Care 24 2001 631 636
34. M.R. Tramer, and B. Walder Number needed to treat (or harm) World Journal of Surgery 29 2005 576 581
35. S.D. Walter Number needed to treat (NNT): Estimation of a measure of clinical benefit Statistics in Medicine 20 2001 3947 3962
36. H. Yki-Jarvinen, A. Dressler, and M. Ziemen Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group Diabetes Care 23 2000 1130 1136
37. Q. Zhang, and L. Menditto Incremental cost savings 6 months following initiation of insulin glargine in a Medicaid fee-for-service sample American Journal of Therapeutics 12 2005 337 343